|
May 3
|
Biotech ImmunoGen Stock Jumps 140% After Positive Drug Trial Data
|
|
May 3
|
ImmunoGen Announces Proposed Public Offering of Common Stock
|
|
May 3
|
Why ImmunoGen Stock Is Soaring Wednesday
|
|
May 3
|
ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soars
|
|
May 3
|
Wall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
|
|
May 3
|
Good News for Patients Is Lifting These 2 Biopharma Stocks
|
|
May 3
|
ELAHEREĀ® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRĪ±-Positive Platinum-Resistant Ovarian Cancer
|
|
May 1
|
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 1
|
ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging
|
|
Apr 30
|
News Flash: Analysts Just Made An Incredible Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts
|
|
Apr 29
|
Q1 2023 ImmunoGen Inc Earnings Call
|
|
Apr 28
|
Why Shares of ImmunoGen Jumped Friday
|
|
Apr 28
|
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 28
|
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
|
|
Apr 21
|
Earnings Preview: ImmunoGen (IMGN) Q1 Earnings Expected to Decline
|